SynthesisAnnals of hematology2026

Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison.

Francesca Palandri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.